SCHEMBL4030640

SCHEMBL4030640

Cc1ncsc1C(=O)NCc1ccc(F)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CHRM4 P08173 5/20 0.53
SCD O00767 1/20 0.52
MMP13 P45452 1/20 0.50
CXCR4 P61073 1/20 0.49
MAOB P27338 1/20 0.46
VHL P40337 1/20 0.45
CACNA1G O43497 2/20 0.45
CACNA1H O95180 2/20 0.45
CACNA1I Q9P0X4 2/20 0.45
PPARG P37231 1/20 0.44
KMT2A Q03164 1/20 0.44
MET P08581 1/20 0.43
P2RX7 Q99572 1/20 0.43
AR P10275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4559627 0.85 SMN1; SMN2 (0.60) SMN1; SMN2L3MBTL1CHRM4SCDVHL
SCHEMBL4025840 0.81 CHRM4 (0.53) SMN1; SMN2L3MBTL1CHRM4KMT2AMET
SCHEMBL3048657 0.80 SMN1; SMN2 (0.59) SMN1; SMN2L3MBTL1CHRM4SCDMMP13
SCHEMBL4205317 0.79 HSD17B13 (0.60) SMN1; SMN2L3MBTL1CHRM4MAOBKMT2A
SCHEMBL243781 0.79 SCD (0.61) CHRM4SCDMMP13CXCR4MAOB
SCHEMBL4362487 0.77 L3MBTL1 (0.54) SMN1; SMN2L3MBTL1CHRM4VHLKMT2A
SCHEMBL5608014 0.76 SCD (0.58) SMN1; SMN2CHRM4SCDCXCR4MAOB
SCHEMBL30309973 0.74 KMT2A (0.51) CHRM4SCDMMP13MAOBCACNA1G
SCHEMBL26654921 0.73 VHL (0.53) MMP13VHLP2RX7
SCHEMBL21101550 0.73 PKM (0.56) SMN1; SMN2L3MBTL1VHLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054408-A2 HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL Novartis Ag (CH) 2009-05-06 EP claimed
WO-2008127349-A2 HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL NOVARTIS AG (CH) 2008-10-23 WO claimed